U.S. Phase 2 Combination Clinical Trial For Non-Small Cell Lung Cancer Patients With K-RAS Or EGFR-Activated Tumours

�Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical test using endovenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center.


"In this era of personalized malignant neoplastic disease treatment, we are quite a excited about this trial," said Dr. Villalona-Calero. "Although we hold had for some time treatments that target EGFR, K-RAS has been an elusive target. REOLYSIN(R) has the potency to objective K-RAS activated tumors, possibly enhancing the beneficial effects produced by chemotherapy."


"This trial gives Oncolytics the opportunity to treat NSCLC patients in a first-line clinical scope," said Dr. Brad Thompson, President and CEO of Oncolytics. "Assuming we achieve an satisfactory response pace, the combination of REOLYSIN(R) with paclitaxel and carboplatin for NSCLC would be a strong candidate for registration studies."



This trial is a single arm, two-stage, open-label, Phase 2 study of REOLYSIN(R) granted intravenously with paclitaxel and carboplatin every 3 weeks. Patients will receive quartet to six cycles of paclitaxel and carboplatin in conjunction with REOLYSIN(R), at which meter REOLYSIN(R) may be continued as a monotherapy. It is hoped-for that up to 36 patients will be tempered in this trial.


Eligible patients include those with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, wHO have non received chemotherapy treatment for their metastatic or recurrent disease. Patients must get demonstrated mutations in K-RAS or EGFR, or EGFR gene amplification in their tumours (metastatic or primary) in parliamentary procedure to condition for the trial.


The primary objectives of the Phase 2 trial are to determine the documentary response pace of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, and to measure progression-free survival at 6 months. The secondary objectives are to specify the median survival and duration of progression-free endurance in patients, and to evaluate the safety and tolerability of REOLYSIN(R) in combination with paclitaxel and carboplatin in this patient population.


REOLYSIN(R) preferentially replicates in cancer cells that have an activated RAS pathway. Approximately two thirds of all cancers let an activated RAS pathway, including to the highest degree metastatic disease. A large number of mutations, including mutations in EGFR, Her2 or K-RAS along the RAS pathway lead to RAS pathway activation.


Recent clinical studies in NSCLC with EGFR-based therapies have shown that patients with mutations or overexpression of EGFR, which are usually found in NSCLC, derive clinical benefit from these therapies. An agent such as REOLYSIN(R) that selectively replicates in cancers with an excited RAS pathway resulting from EGFR mutations or overexpression may show similar benefit. However, patients with mutant K-RAS, or up to 20% of the more than than 180,000 patients diagnosed every year in the U.S. with NSCLC, do non derive benefit from EGFR-based therapies. The introduction of screening for K-RAS mutations, and the exclusion of K-RAS mutated patients will lead to higher reply rates in EGFR-mutated or overexpressed patients treated with EGFR- based therapies. This excluded patient group is therefore prescreened for RAS pathway activation resulting from mutations in K-RAS, and an agent such as REOLYSIN(R) crataegus laevigata be indicated for this patient mathematical group. This study targets patients with either EGFR-activated tumours or K-RAS mutations.


"Previous preclinical information indicates that reovirus tends to place in the lungs, and we have seen clinical responses in metastatic lung lesions with REOLYSIN(R) as a monotherapy or in combination with paclitaxel and carboplatin," aforesaid Dr. Brad Thompson, President and CEO of Oncolytics. "A pregnant clinical chance for REOLYSIN(R) is in the treatment of patients with metastatic cancers including NSCLC world Health Organization have a mutated K-RAS gene and are unbelievable to respond to treatment with EGF receptor inhibitors."

About Lung Cancer


Lung cancer is the second near common cancer the Crab in workforce and women and is the leading cause of cancer decease. More people die of lung crab than of colon, breast and prostate gland cancers combined. During 2008, there volition be about 215,020 new cases of lung cancer in the U.S., of which 85% to 90% testament be NSCLC. Only around 15% of people diagnosed with lung cancer ar still alive after phoebe years. There is no single, first-line therapy sanctioned for NSCLC in the U.S., just first-line combination treatments include

Do You Have What It Takes To Be The Jonas Brothers Girlfriend?

...more Selena Gomez �
...more The Jonas Brothers �
...more Miley Cyrus �

Following on from an earlier admittance about their ideal daughter, the Jonas Brothers experience given more details around what they expect from a possible future partner.


The rocker siblings have a wave of eager fans who would love zip more than be wooed by one of the boys, but there ar some requirements which they would bear to match first.


Heartthrob Joe does not want a girlfriend world Health Organization constantly whined. He explains: "If they are shrewish and irritation, you're like, 'Go away'."


Meanwhile, eldest member Kevin doesn�t think he has sentence for a girlfriend. Not even an Italian one?


The 20-year-old says: "We're not ever in truth with people, 'cause we're always travelling. And you get on the earphone and they're like, 'My day is awful, blah,' and you're like, 'This is not what I pauperization right now!'"


However, cutie Nick, who has dated Miley Cyrus and is like a shot romantically coupled to Selena Gomez, has only unmatchable requirement. He lovingly says: "They feature to be good to their moms."

Risk Of Prostate Cancer After Diagnosis Of Atypical Glands Suspicious For Carcinoma On Saturation And Traditional Biopsies

�UroToday.com - In the September 2008 issue of the Journal of Urology, Dr. Robert Abouassaly and associates from the Cleveland Clinic reported that the finding of atypia on prostate biopsy is associated with a high likeliness of inherent malignancy, regardless of the number of cores taken at the initial biopsy.


The investigators performed this study, because some have suggested that equivocal findings, such as atypia, are due to inadequate prostate sampling at initial biopsy. The chemical group retrospectively determined the peril of prostate gland cancer (CaP) at reiterate biopsy in patients with atypia diagnosed on saturation biopsy. Between 2001 and 2007, a total of 4,139 prostate biopsies were entered into the Cleveland Clinic database, of which 1,068 were saturation. From these, 57 had atypia on initial biopsy and underwent rebiopsy. Nineteen patients had atypia diagnosed on saturation biopsy (20 cores or greater) and 38 had atypia diagnosed victimisation a traditional biopsy proficiency.


Median patient role age was 62 eld, median PSA was 5.0ng/ml, and median time between biopsies was 5 months. Eight of 19 patients (42%) were diagnosed with CaP on replicate biopsy, of whom 7 had Gleason score 6 and 1 had Gleason score 10 CaP. Of the 38 men with atypia on initial biopsy, 15 (39%) had CaP on reprise biopsy. Ten men had Gleason scotch 6, tetrad had Gleason score 7 and 1 had Gleason score 9 CaP. The only divergence between the groups was the men with an initial saturation biopsy were more likely to get concomitant inflaming diagnosed on the initial biopsy. Patients with CaP were less likely to have redness seen at the initial biopsy; only when 5 of 22 work force (23%) with inflammation at initial biopsy had CaP on repeat biopsy compared to 18 of 35 (51%) without inflammation.


These data hint that under-sampling the prostate may not be a factor resulting in the diagnosis of atypia.


Abouassaly R, Tan N, Moussa A, Jones JS

J Urol. 2008 Jul 15. Epub ahead of print.

10.1016/j.juro.2008.05.019


Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS

UroToday - the only urology website with original content written by global urology key view leaders actively engaged in clinical practice.


To access the latest urology news releases from UroToday, go to:
www.urotoday.com


Copyright � 2008 - UroToday



More info

• Breast Cancer Recurrence Debate Rages
• Fewer than half of Nunavut’s doctors actually live there
• Happiness keeps the doctor away
• Pom Poms, Cheers… and Broken Bones?
• Stress can make allergies worse

The Platters

   
Artist: The Platters

   Genre(s): 
Jazz
   

---

Discography:


   
 The Original Platters: The Very Best Of

   Year: 1987   
Tracks: 16


   
 Selection CD 1 of 2

   Year:    
Tracks: 36

---

 





Late-Night Follies

Re-activated

   
Artist: Re-activated

   Genre(s): 
Industrial
   

---

Discography:


   
 Taste the Caustic

   Year: 2000   
Tracks: 14

---

 

Nando Reis Acustico

   
Artist: Nando Reis Acustico

   Genre(s): 
Other
   

---

Discography:


   
 MTV

   Year:    
Tracks: 18

---

 





Michelle Williams - The Things They Say 8399

Black Lips, Stephen Malkmus And The Jicks added to Hydro Connect bill

Black Lips, and have been added to the line-up of the forthcoming Hydro Connect festival.

The bash, which also features the likes of Franz Ferdinand, Kasabian and Bloc Party, is set to take place near Argyll, Scotland on August 29-31.

The festival claims to be a committed carbon neutral festival, placing emphasis on being eco-friendly.

To check the availability of Hydro Connect tickets and get all the latest listings, go to NME.COM/GIGS now, or call 0871 230 1094.